Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi‐center HGB ‐206 trial-Reference-Cited by-同舟云学术

Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi‐center HGB ‐206 trial

Published:2020-06-03 Issue:9 Volume:95 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Tisdale John F.¹^ORCID,Pierciey Francis J.²,Bonner Melissa²,Thompson Alexis A.³⁴^ORCID,Krishnamurti Lakshmanan⁵^ORCID,Mapara Markus Y.⁶,Kwiatkowski Janet L.⁷⁸^ORCID,Shestopalov Ilya²,Ribeil Jean‐Antoine²^ORCID,Huang Wenmei²,Asmal Mohammed²,Kanter Julie⁹^ORCID,Walters Mark C.¹⁰^ORCID

Affiliation:

1. Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute National Institutes of Health Bethesda Maryland USA

2. bluebird bio Cambridge Massachusetts USA

3. Division of Hematology, Oncology & Stem Cell Transplant Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois USA

4. Department of Pediatrics, Feinberg School of Medicine, Northwestern University Chicago Illinois USA

5. Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta Emory University Atlanta Georgia USA

6. Division of Hematology/Oncology, Columbia Center for Translational Immunology Columbia University Medical Center New York New York USA

7. Division of Hematology Children's Hospital of Philadelphia Philadelphia Pennsylvania USA

8. Department of Pediatrics University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA

9. Division of Hematology/Oncology University of Alabama at Birmingham Birmingham Alabama USA

10. University of California San Francisco, Benioff Children's Hospital Oakland Oakland California USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25867

Reference6 articles.

1. Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion

2. Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?

3. Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients

4. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34 + hematopoietic progenitor cells in patients with sickle cell disease: interim results

5. Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gene Therapies for Sickle Cell Disease;Journal of Pharmacy Technology;2024-08-15

2. Cxcl10 and Cxcr3 regulate self-renewal and differentiation of hematopoietic stem cells;Stem Cell Research & Therapy;2024-08-07

3. Mobilization and collection of CD34 + cells in patients with globin disorders: Providing the starting material to manufacturers of autologous gene therapies;Transfusion and Apheresis Science;2024-06

4. Current state of gene therapy in sickle cell disease;Vox Sanguinis;2024-03-15

5. Effect of voxelotor on murine bone marrow and peripheral blood with hematopoietic progenitor cell mobilization for gene therapy of sickle cell disease;Blood Cells, Molecules, and Diseases;2024-03